|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Uemura N, Okamoto S, Yamamoto S, Matsumura
N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N and Schlemper RJ:
Helicobacter pylori infection and the development of gastric
cancer. N Engl J Med. 345:784–789. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nobili S, Bruno L, Landini I, Napoli C,
Bechi P, Tonelli F, Rubio CA, Mini E and Nesi G: Genomic and
genetic alterations influence the progression of gastric cancer.
World J Gastroenterol. 17:290–299. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qu Y, Dang S and Hou P: Gene methylation
in gastric cancer. Clin Chim Acta. 424:53–65. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oue N, Mitani Y, Motoshita J, Matsumura S,
Yoshida K, Kuniyasu H, Nakayama H and Yasui W: Accumulation of DNA
methylation is associated with tumor stage in gastric cancer.
Cancer. 106:1250–1259. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
|
8
|
Baylin SB and Herman JG: DNA
hypermethylation in tumorigenesis: Epigenetics joins genetics.
Trends Genet. 16:168–174. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lerman MI and Minna JD: The 630-kb lung
cancer homozygous deletion region on human chromosome 3p21.3:
Identification and evaluation of the resident candidate tumor
suppressor genes. The International Lung Cancer Chromosome 3p213
Tumor Suppressor Gene Consortium. Cancer Res. 60:6116–6133.
2000.PubMed/NCBI
|
|
10
|
Masselink H and Bernards R: The adenovirus
E1A binding protein BS69 is a corepressor of transcription through
recruitment of N-CoR. Oncogene. 19:1538–1546. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wolford JK and Prochazka M: Structure and
expression of the human MTG8/ETO gene. Gene. 212:103–109. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Agathanggelou A, Dallol A,
Zöchbauer-Müller S, Morrissey C, Honorio S, Hesson L, Martinsson T,
Fong KM, Kuo MJ, Yuen PW, et al: Epigenetic inactivation of the
candidate 3p21.3 suppressor gene BLU in human cancers. Oncogene.
22:1580–1588. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cheng Y, Ho RL, Chan KC, Kan R, Tung E,
Lung HL, Yau WL, Cheung AK, Ko JM, Zhang ZF, et al: Anti-angiogenic
pathway associations of the 3p213 mapped BLU gene in nasopharyngeal
carcinoma. Oncogene. Oct 27;2014 (Epub ahead of print). View Article : Google Scholar : 2014.
|
|
14
|
Zhang X, Liu H, Li B, Huang P, Shao J and
He Z: Tumor suppressor BLU inhibits proliferation of nasopharyngeal
carcinoma cells by regulation of cell cycle, c-Jun N-terminal
kinase and the cyclin D1 promoter. BMC Cancer. 12:2672012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park ST, Byun HJ, Kim BR, Dong SM, Park
SH, Jang PR and Rho SB: Tumor suppressor BLU promotes paclitaxel
antitumor activity by inducing apoptosis through the downregulation
of Bcl-2 expression in tumorigenesis. Biochem Biophys Res Commun.
435:153–159. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoo HJ, Kim BR, Byun HJ, Park SY and Rho
SB: BLU enhances the effects of anti-angiogenic activity in
combination with gemcitabine-based chemotherapeutic agents. Int J
Biochem Cell Biol. 45:1236–1245. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lai HC, Lin YW, Chang CC, Wang HC, Chu TW,
Yu MH and Chu TY: Hypermethylation of two consecutive tumor
suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical
neoplasias. Gynecol Oncol. 104:629–635. 2007. View Article : Google Scholar
|
|
18
|
Ito M, Ito G, Kondo M, Uchiyama M, Fukui
T, Mori S, Yoshioka H, Ueda Y, Shimokata K and Sekido Y: Frequent
inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter
hypermethylation and allele loss in non-small cell lung cancer.
Cancer Lett. 225:131–139. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yi Lo PH, Chung Leung AC, Xiong W, Law S,
Duh FM, Lerman MI, Stanbridge EJ and Lung ML: Expression of
candidate chromosome 3p21.3 tumor suppressor genes and
downregulation of BLU in some esophageal squamous cell carcinomas.
Cancer Lett. 234:184–192. 2006. View Article : Google Scholar
|
|
20
|
Hesson L, Bièche I, Krex D, Criniere E,
Hoang-Xuan K, Maher ER and Latif F: Frequent epigenetic
inactivation of RASSF1A and BLU genes located within the critical
3p21.3 region in gliomas. Oncogene. 23:2408–2419. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qiu GH, Tan LK, Loh KS, Lim CY, Srivastava
G, Tsai ST, Tsao SW and Tao Q: The candidate tumor suppressor gene
BLU, located at the commonly deleted region 3p21.3, is an
E2F-regulated, stress-responsive gene and inactivated by both
epigenetic and genetic mechanisms in nasopharyngeal carcinoma.
Oncogene. 23:4793–4806. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang X, Yang R, Jia Y, Cai D, Zhou B, Qu
X, Han H, Xu L, Wang L, Yao Y, et al: Hypermethylation of Sp1
binding site suppresses hypothalamic POMC in neonates and may
contribute to metabolic disorders in adults: Impact of maternal
dietary CLAs. Diabetes. 63:1475–1487. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guo D, Wu B, Yan J, Li X, Sun H and Zhou
D: A possible gene silencing mechanism: Hypermethylation of the
Keap1 promoter abrogates binding of the transcription factor Sp1 in
lung cancer cells. Biochem Biophys Res Commun. 428:80–85. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ehrlich S, Weiss D, Burghardt R,
Infante-Duarte C, Brockhaus S, Muschler MA, Bleich S, Lehmkuhl U
and Frieling H: Promoter specific DNA methylation and gene
expression of POMC in acutely underweight and recovered patients
with anorexia nervosa. J Psychiatr Res. 44:827–833. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Campanero MR, Armstrong MI and Flemington
EK: CpG methylation as a mechanism for the regulation of E2F
activity. Proc Natl Acad Sci USA. 97:6481–6486. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lania L, Majello B and De Luca P:
Transcriptional regulation by the Sp family proteins. Int J Biochem
Cell Biol. 29:1313–1323. 1997. View Article : Google Scholar
|
|
27
|
Emili A, Greenblatt J and Ingles CJ:
Species-specific interaction of the glutamine-rich activation
domains of Sp1 with the TATA box-binding protein. Mol Cell Biol.
14:1582–1593. 1994.PubMed/NCBI
|
|
28
|
Yuan H, Gong A and Young CY: Involvement
of transcription factor Sp1 in quercetin-mediated inhibitory effect
on the androgen receptor in human prostate cancer cells.
Carcinogenesis. 26:793–801. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qian Q, Shi X, Lei Z, Zhan L, Liu RY, Zhao
J, Yang B, Liu Z and Zhang HT: Methylated +58CpG site decreases DCN
mRNA expression and enhances TGF-β/Smad signaling in NSCLC cells
with high metastatic potential. Int J Oncol. 44:874–882.
2014.PubMed/NCBI
|
|
30
|
Dynan WS and Tjian R: The
promoter-specific transcription factor Sp1 binds to upstream
sequences in the SV40 early promoter. Cell. 35:79–87. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hundahl SA, Phillips JL and Menck HR: The
National Cancer Data Base Report on poor survival of U.S. gastric
carcinoma patients treated with gastrectomy: Fifth Edition American
Joint Committee on Cancer staging, proximal disease, and the
‘different disease’ hypothesis. Cancer. 88:921–932. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dikken JL, van de Velde CJ, Coit DG, Shah
MA, Verheij M and Cats A: Treatment of resectable gastric cancer.
Therap Adv Gastroenterol. 5:49–69. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mickevicius A, Ignatavicius P, Markelis R,
Parseliunas A, Butkute D, Kiudelis M, Endzinas Z, Maleckas A and
Dambrauskas Z: Trends and results in treatment of gastric cancer
over last two decades at single East European centre: A cohort
study. BMC Surg. 14:982014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Forman D and Burley VJ: Gastric cancer:
Global pattern of the disease and an overview of environmental risk
factors. Best Pract Res Clin Gastroenterol. 20:633–649. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rahman R, Asombang AW and Ibdah JA:
Characteristics of gastric cancer in Asia. World J Gastroenterol.
20:4483–4490. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chiang YC, Chang MC, Chen PJ, Wu MM, Hsieh
CY, Cheng WF and Chen CA: Epigenetic silencing of BLU through
interfering apoptosis results in chemoresistance and poor prognosis
of ovarian serous carcinoma patients. Endocr Relat Cancer.
20:213–227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wanajo A, Sasaki A, Nagasaki H, Shimada S,
Otsubo T, Owaki S, Shimizu Y, Eishi Y, Kojima K, Nakajima Y, et al:
Methylation of the calcium channel-related gene, CACNA2D3, is
frequent and a poor prognostic factor in gastric cancer.
Gastroenterology. 135:580–590. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jones PA and Laird PW: Cancer epigenetics
comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Batistuzzo de Medeiros SR, Krey G, Hihi AK
and Wahli W: Functional interactions between the estrogen receptor
and the transcription activator Sp1 regulate the estrogen-dependent
transcriptional activity of the vitellogenin A1 io promoter. J Biol
Chem. 272:18250–18260. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Christman JK: 5-Azacytidine and
5-aza-2′-deoxycytidine as inhibitors of DNA methylation:
Mechanistic studies and their implications for cancer therapy.
Oncogene. 21:5483–5495. 2002. View Article : Google Scholar : PubMed/NCBI
|
